mRNA |
myriocin |
CTRPv2 |
pan-cancer |
AAC |
-0.074 |
0.3 |
mRNA |
GSK461364 |
CTRPv2 |
pan-cancer |
AAC |
0.03 |
0.3 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.032 |
0.3 |
mRNA |
BRD-K99584050 |
CTRPv2 |
pan-cancer |
AAC |
-0.05 |
0.3 |
mRNA |
tigecycline |
CTRPv2 |
pan-cancer |
AAC |
-0.046 |
0.4 |
mRNA |
selumetinib:decitabine (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.031 |
0.4 |
mRNA |
BMS-195614 |
CTRPv2 |
pan-cancer |
AAC |
-0.036 |
0.4 |
mRNA |
decitabine |
CTRPv2 |
pan-cancer |
AAC |
-0.026 |
0.4 |
mRNA |
salermide |
CTRPv2 |
pan-cancer |
AAC |
0.043 |
0.4 |
mRNA |
betulinic acid |
CTRPv2 |
pan-cancer |
AAC |
-0.035 |
0.4 |